Skip To Main Content
Subear Hussein on Muck Rack

Subear Hussein

As seen in: Nature
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Subear

Contact Subear, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Teclistamab versus lenalidomide-dexamethasone in high-risk smoldering multiple myeloma: a randomized phase 2 trial

|
By Omar Nadeem, Sophie Magidson, Jeffrey Matous, Eva Medvedova, Elizabeth O’Donnell, Robert A. Redd, Yuxin Liu, Shonali Midha, Adam S. Sperling, Frances Arters, Christine Davie, Caroline Ricciardi, Nayda Bidikian, Jean-Baptiste Alberge, Sungjae Kim, Francesco Corrado, Hannah Ashton, Siham A. Mohamed, Ashlee Sturtevant, Marjorie Marto, Amy E. Bergeron, Francesco Malfona, Kevin Panaro, Paul Richardson, Jerome Ritz, Lorenzo Trippa, Irene M. Ghobrial, Rosa Toenges, Subear Hussein, Lorena Pantano-Rubino, Daniel Addonizio
| Nature Verified
Abstract Teclistamab, a B cell maturation antigen-targeting bispecific antibody, has demonstrated substantial activity in relapsed multiple myeloma (MM), particularly in earlier lines of therapy, and may have higher efficacy in high-risk smoldering MM (HR-SMM) with a more functional immune system. In the randomized phase 2 ImmunoPRISM trial, we compared fixed-duration teclistamab with lenalidomide–dexamethasone (Rd) in HR-SMM.
Open in Who Shared Issue with article?
See all 1 articles